Compare Jabil Inc (JBL) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs DENTSPLY SIRONA Inc — how do they compare? Jabil Inc trades at $305.62 (market cap $31.35B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: Jabil Inc is far larger — about 18.1× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| JBL | XRAY | |
|---|---|---|
Market Cap | $31.35B | $1.73B |
Volume | 1,337,978 | 6,198,582 |
Sector | Technology | Health |
52-Week High | $385.50 | $14.68 |
52-Week Low | $192.49 | $8.52 |
Typical Hold Time | 23 Days | 72 Days |
Enterprise Value | $33.63B | $3.80B |
Dividend Yield | 0.11% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $305.83, up 2.12% with strong Q4 2026 earnings beating estimates at $4.40 EPS versus $4.07 expected. Technical indicators show bearish signals with price near resistance at $304, while fundamentals reveal robust revenue growth to $36.0B projected for 2026 and a high ROE of 74.11%. Recent news highlights AI infrastructure demand driving fiscal 2027 growth targets of 24%.
The outlook is positive with analyst consensus price target of $434.75 implying 42% upside, supported by 14 buy ratings and no sells. Risks include high debt levels and market volatility despite strong earnings, but AI-driven expansion and consistent earnings beats present a compelling growth opportunity for investors.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
